Clinical trial for patients with small-cell lung cancer (Progressing after chemotherapy)

Clinical Research Center «BioEq» invites patients to participate in the phase III clinical study for evaluation of the original immune drug in comparison with topotecan for patients with advanced or metastasized small-cell lung cancer with high expression of DLL3, who was diagnosed with disease progression after the first-line platinum based chemotherapy.

 Investigational Product: original immune drug.

 Comparator Product: topotecan.

 All examinations and medications are provided on a free of charge basis. «BioEq» provides taxi for all visits, except the first one.

 We invite men and women starting from 18 years old with:

  •         Diagnosed advanced or metastasized small-cell lung cancer
  •         First disease progression during or after first line systematic therapy based on platinum-based therapy

If you are interested in this research or you have questions about participation, you can contact us during the business days from 10 am to 6 pm at  8-812-945-22-32